Relmada (RLMD) Climbs 5.00% on June 22

Equities Staff  |

Relmada Therapeutics Inc (NASDAQ: RLMD) shares have risen 5.00%, or $0.92 per share, as on 12:09:01 est today. Opening the day at $18.09, 70,001 shares of Relmada exchanged hands and the stock has moved between $19.67 and $18.09.  

This year the company has a YTD change of 18.38%.

Relmada anticipates its next earnings on 2022-08-04.

For technical charts, analysis, and more on Relmada visit the company profile.

About Relmada Therapeutics Inc

Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Its experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada' s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 has entered late-stage development as an adjunctive treatment for MDD in adults.

To get more information on Relmada Therapeutics Inc and to follow the company's latest updates, you can visit the company's profile page here: Relmada Therapeutics Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

The Best Laid Plans of Mice and Men — Part II
Why I’m Buying the 'New' Value Stocks
Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade



Market Movers

Sponsored Financial Content